A Case Report of AQP4-IgG-seropositive Refractory Neuromyelitis Optica Spectrum Disorder Patient with Sjögren's Syndrome and Pancytopenia Treated with Inebilizumab

Overview

Journal Front Neurol

Specialty Neurology

Date 2024 Jun 20

PMID 38899058

Authors

Shasha Li

Yuting Gao

Yang He

Zhaoxu Zhang

Affiliations

Soon will be listed here.

Abstract

Patients with neuromyelitis optica spectrum disorder (NMOSD) coexisting with both Sjögren's syndrome (SS) and pancytopenia are exceptionally rare. There is no study on the treatment of such patients. We presented a case of AQP4-IgG seropositive refractory NMOSD patient combined with SS and pancytopenia with significant response to inebilizumab. In 2017 the 49-year-old female patient was diagnosed with SS and pancytopenia without any treatment. In August 2022, she had a sudden onset of lower limbs weakness, manifested as inability to walk, accompanied by urinary incontinence. After receiving methylprednisolone and cyclophosphamide, she regained the ability to walk. In February 2023, she suffered from weakness of both lower limbs again and paralyzed in bed, accompanied by retention of urine and stool, and loss of vision in both eyes. After receiving methylprednisolone and three plasmapheresis, the condition did not further worsen, but there was no remission. In March 2023, the patient was admitted to our hospital and was formally diagnosed with AQP4-IgG seropositive NMOSD combined with SS and pancytopenia. After receiving two 300 mg injections of inebilizumab, not only the symptoms of NMOSD improved significantly, but also the symptoms of concurrent SS and pancytopenia. In the cases of AQP4-IgG seropositive NMOSD who have recurrent episodes and are comorbid with other autoimmune disorders, inebilizumab may be a good choice.

References

Pittock S, Lucchinetti C . Neuromyelitis optica and the evolving spectrum of autoimmune aquaporin-4 channelopathies: a decade later. Ann N Y Acad Sci. 2015; 1366(1):20-39. PMC: 4675706. DOI: 10.1111/nyas.12794. View

Bennett J, Aktas O, Rees W, Smith M, Gunsior M, Yan L . Association between B-cell depletion and attack risk in neuromyelitis optica spectrum disorder: An exploratory analysis from N-MOmentum, a double-blind, randomised, placebo-controlled, multicentre phase 2/3 trial. EBioMedicine. 2022; 86:104321. PMC: 9664402. DOI: 10.1016/j.ebiom.2022.104321. View

Shahmohammadi S, Doosti R, Shahmohammadi A, Mohammadianinejad S, Sahraian M, Azimi A . Autoimmune diseases associated with Neuromyelitis Optica Spectrum Disorders: A literature review. Mult Scler Relat Disord. 2018; 27:350-363. DOI: 10.1016/j.msard.2018.11.008. View

Liu L, Tang L, Zhang L, Li X, Huang P, Xiong J . The First Case Report of Preschool-Onset SS/SLE Coexisting With NMOSD of Chinese Origin. Front Immunol. 2022; 13:887041. PMC: 9108358. DOI: 10.3389/fimmu.2022.887041. View

Javed A, Balabanov R, Arnason B, Kelly T, Sweiss N, Pytel P . Minor salivary gland inflammation in Devic's disease and longitudinally extensive myelitis. Mult Scler. 2008; 14(6):809-14. DOI: 10.1177/1352458508088941. View

Mavragani C, Moutsopoulos H . The geoepidemiology of Sjögren's syndrome. Autoimmun Rev. 2009; 9(5):A305-10. DOI: 10.1016/j.autrev.2009.11.004. View

Macaron G, Khoury J, Bena J, Seay M, Bermel R, Cohen J . Early age of onset predicts severity of visual impairment in patients with neuromyelitis optica spectrum disorder. Mult Scler. 2021; 27(11):1749-1759. DOI: 10.1177/1352458520981736. View

Carubbi F, Cipriani P, Marrelli A, Benedetto P, Ruscitti P, Berardicurti O . Efficacy and safety of rituximab treatment in early primary Sjögren's syndrome: a prospective, multi-center, follow-up study. Arthritis Res Ther. 2013; 15(5):R172. PMC: 3979092. DOI: 10.1186/ar4359. View

Fox R . Sjögren's syndrome. Lancet. 2005; 366(9482):321-31. DOI: 10.1016/S0140-6736(05)66990-5. View

10.

Aungsumart S, Apiwattanakul M . Clinical outcomes and predictive factors related to good outcomes in plasma exchange in severe attack of NMOSD and long extensive transverse myelitis: Case series and review of the literature. Mult Scler Relat Disord. 2017; 13:93-97. DOI: 10.1016/j.msard.2017.02.015. View

11.

Qin C, Tao R, Zhang S, Chen B, Chen M, Yu H . Predictive Factors of Resistance to High-Dose Steroids Therapy in Acute Attacks of Neuromyelitis Optica Spectrum Disorder. Front Neurol. 2020; 11:585471. PMC: 7688779. DOI: 10.3389/fneur.2020.585471. View

12.

Shiboski C, Shiboski S, Seror R, Criswell L, Labetoulle M, Lietman T . 2016 American College of Rheumatology/European League Against Rheumatism Classification Criteria for Primary Sjögren's Syndrome: A Consensus and Data-Driven Methodology Involving Three International Patient Cohorts. Arthritis Rheumatol. 2016; 69(1):35-45. PMC: 5650478. DOI: 10.1002/art.39859. View

13.

Kleiter I, Gahlen A, Borisow N, Fischer K, Wernecke K, Hellwig K . Apheresis therapies for NMOSD attacks: A retrospective study of 207 therapeutic interventions. Neurol Neuroimmunol Neuroinflamm. 2018; 5(6):e504. PMC: 6192689. DOI: 10.1212/NXI.0000000000000504. View

14.

Kim H, Lee E, Kim S, Choi L, Kim H, Kim H . Longitudinal follow-up of serum biomarkers in patients with neuromyelitis optica spectrum disorder. Mult Scler. 2021; 28(4):512-521. DOI: 10.1177/13524585211024978. View

15.

Hor J, Asgari N, Nakashima I, Broadley S, Leite M, Kissani N . Epidemiology of Neuromyelitis Optica Spectrum Disorder and Its Prevalence and Incidence Worldwide. Front Neurol. 2020; 11:501. PMC: 7332882. DOI: 10.3389/fneur.2020.00501. View

16.

Rensel M, Zabeti A, Mealy M, Cimbora D, She D, Drappa J . Long-term efficacy and safety of inebilizumab in neuromyelitis optica spectrum disorder: Analysis of aquaporin-4-immunoglobulin G-seropositive participants taking inebilizumab for ⩾4 years in the N-MOmentum trial. Mult Scler. 2021; 28(6):925-932. PMC: 9024030. DOI: 10.1177/13524585211047223. View

17.

Berkowitz A, Samuels M . The neurology of Sjogren's syndrome and the rheumatology of peripheral neuropathy and myelitis. Pract Neurol. 2013; 14(1):14-22. DOI: 10.1136/practneurol-2013-000651. View

18.

Marignier R, Pittock S, Paul F, Kim H, Bennett J, Weinshenker B . AQP4-IgG-seronegative patient outcomes in the N-MOmentum trial of inebilizumab in neuromyelitis optica spectrum disorder. Mult Scler Relat Disord. 2022; 57:103356. DOI: 10.1016/j.msard.2021.103356. View

19.

Sellner J, Boggild M, Clanet M, Hintzen R, Illes Z, Montalban X . EFNS guidelines on diagnosis and management of neuromyelitis optica. Eur J Neurol. 2010; 17(8):1019-32. DOI: 10.1111/j.1468-1331.2010.03066.x. View

20.

Huang X, Wu J, Xiao Y, Zhang Y . Timing of plasma exchange for neuromyelitis optica spectrum disorders: A meta-analysis. Mult Scler Relat Disord. 2021; 48:102709. DOI: 10.1016/j.msard.2020.102709. View